Aktiesnakken — Juli 2010
-
We are delighted to inform your about the amendment
-
in very short order we have found a win win way
-
major keystone
-
blockbuster flagship er Arzerra
-
we are now capable to leverage GSK financial power
-
market concerns
-
Markedet har været nervøs for fabrikssalg, emission og ofab
-
today announcement addresses these concerns
-
de overtager RA fra 1. Januar 2010!
-
GSK planlægger en række fase 2 forsøg her
-
MS fase 2 om nogle uger
-
Oncology - vi fortsætter som tidligere, med et loft på 17 mill Pund per year
-
royalites er det samme!
-
milestones cut med 50%
-
men fase 3 med bemadustine bliver betalt in FULL
-
de trækker deres forrige guidance tilbage!
-
fully revised kommer 17. august
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind